Proceeds from Enavate's investment will help to advance clinical development of GV101 and Graviton's pipeline of ROCK2 inhibitors to treat a range of serious fibrotic, inflammatory and neurologic conditions.
The funding represents the eighth portfolio investment Enavate has made in partner companies to date and follows
ROCK2 is an effector of the small GTPase Rho and belongs to the AGC family of kinases. It is implicated in the pathology of multiple diseases, including metabolic, autoimmune, inflammatory and neurologic disorders for which there is either inadequate or no treatment at all. Graviton's team previously successfully pioneered the development of Rezurock, the first approved ROCK2 inhibitor, for graft vs. host disease.
'Enavate recognizes the enormous potential for novel ROCK2 therapies to treat severe medical conditions,' said
'Finding safe and effective treatments for conditions that currently have no cure is our priority,' added
In conjunction with the financing,
About Enavate Sciences
Enavate Sciences is a portfolio company of
About Graviton Bioscience
Graviton Bioscience is a clinical stage drug discovery and development company, dedicated to engineering and developing best-in-class therapeutics for treating CNS, autoimmune, fibrotic and other serious diseases where ROCK2 plays a pivotal role in pathology. Graviton's first drug candidate GV101 is in clinical studies, with additional assets advancing through the preclinical pipeline. Leading the company is Dr.
About GV101
GV101 is a best-in-class, clinical-stage selective inhibitor of Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2) with blood-brain-barrier penetration capability, as demonstrated in preclinical studies. GV101 is in clinic in an ongoing Phase 1 multiple ascending dose trial in healthy volunteers and has achieved clinically relevant exposure with a favorable safety profile. A separate formulation of GV101 has completed a Phase 1 single and multiple ascending dose trial in
Contact:
Julia Balanova
Email: Julia.Balanova@gravitoncorp.com
Email: Enavate@DLPR.com
(C) 2024 Electronic News Publishing, source